|
Presentations
American Society of Gene and Cell Therapy, May 2011
“Initiation of clinical trials using a Retroviral Replicating Vector encoding a modified cytosine deaminase (Toca 511) in recurrent high grade glioma patients”. D. J. Jolly, et. al.
6th Oncolytic Virus Conference, March 2011
“Prostate-specific retroviral replicating vectors: tumor cell selectivity and cytotoxicity studies”. S. Kamijima, et. al.
European Society of Gene Therapy 18th Annual Congress, October 2010
“Replicating Retrovirus Encoding a Prodrug Activator (Toca 511) Enters Clinic for the Treatment of Glioblastoma Multiforme (GBM)”. D. J. Jolly, et. al.
AACR, July 2010
“Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a novel prodrug activator gene transfer technology in an immune-competent model of glioblastoma”. D. Ostertag, et. al.
View abstract.
Japan Society of Gene Therapy, July 2010
“Progress to the clinic of a novel prodrug activator gene transfer technology for the treatment of cancer”. D. J. Jolly, et al.
46th Annual DIA conference, June 2010
“Replicative and Nonreplicative Retroviral Vectors in the Clinic: Horses for Courses”. D. J. Jolly, et. al.
American Society of Gene and Cell Therapy, May 2010
“Clinical Trial Entry of a Novel Prodrug Activator Gene Transfer Technology for the Treatment of Cancer”. H. E. Gruber, et. al.
AACR Genetics and Biology of Brain Cancers, December 2009
"Robust therapeutic effect of replication competent murine leukemia virus vector carrying cytosine deaminase gene (Toca 511) in combination with 5-fluorocytosine in 3 brain tumor models in mice". J. M. Robbins, et. al.
The Sixteenth West Coast Retrovirus Meeting, October 2009
“Determination of Biological Activity of Replication-Competent Retroviral Vectors”. R. Burnett, et. al.
Society for CNS Interstitial Delivery of Therapeutics, September 2009
"Treating GBM Using a Replication Competent Retrovirus". D. Pertschuk, MD.
Japanese Society of Gene Therapy Annual Meeting, July 2009
"Improved Prodrug Activator Gene Therapy for Cancer". H. E. Gruber, MD., et al.
NIH Recombinant DNA Advisory Committee (RAC) Meeting, June 2009
M. Aghi, D. Jolly, D. Pertschuk
Click to view the RAC's Website and Webcast.
Slide the button to 4:47 minutes to view Tocagen's presentation.
American Society of Gene Therapy, May 2009
"Potency Assays: How Do You Define Product Activity?". C. E. Ibañez, Ph.D.
Biotechnology Industry Organization, June 2008
"Myth Versus Reality in Gene Therapy". D. J. Jolly, Ph.D.
British Society for Gene Therapy Annual Meeting, March 2008
"Integration of Gene Delivery and Drug Development". D. J. Jolly, Ph.D.
Phacilitate Cell & Gene Therapy Conference, January 2008
"Strategies in Finding a Way Through the Patent and Licensing Maze in Gene Therapy". D. J. Jolly, Ph.D.
|
